APAC BCG Vaccine Market

Asia Pacific BCG Vaccine Market Size & Growth (2023 to 2028):

As per the research report, the Asia Pacific BCG Vaccine Market size was valued at USD 10.44 billion in 2023 and is expected to grow at a CAGR of 7 %, to reach USD 14.65 billion by 2028 from 2023 to 2028. 

The Increasing number of Tuberculosis cases, surging BCG immunization coverage, and technological advancements in vaccine development are driving the BCG vaccine market growth. Also, the change of TB in the adult stage of society is likely to boost demand throughout the forecast period. 

The growing senior population in emerging countries such as China and India significantly increases the demand for the BCG vaccines daily. 

Other factors such as improving healthcare infrastructure, high healthcare spending, and favorable government policies in the region boost market growth. 

However, the growing disease outbreaks influence supply and demand dynamics and may determine increased demand for BCG vaccination and the future evolution of the BCG vaccine pipeline.

The Initiatives taken by the government for creating awareness among the people about the BCG vaccines and immunization programs are most likely to accelerate the market growth. 

Furthermore, the BCG vaccine market is developing significantly in the region because the key companies are focusing upon the regional market's growth by implanting various market strategies. The strategies include partnerships, mergers, and acquisitions. 

However, problems such as the BCG vaccine's adverse effects, such as swollen glands and headaches, are projected to limit market growth throughout the projection period.

In addition, demand inflexibility poses a problem to the sector; the emerging countries in the region are also experiencing supply issues. The government's minimal investment in vaccine manufacture impacts availability and output. Furthermore, unpleasant vaccination side effects and global supply constraints are projected to hamper market expansion throughout the projection period.

This research report on the Asia Pacific BCG Vaccine Market has been segmented and sub-segmented into the following categories.

By Demographics:

• Pediatrics (0-18 years)
• Adults (19-35 years)

By Product Type:

• BCG Vaccine 
• Immune BCG
• Therapy BCG          

By End User:

• Pediatrics
• Adults       

By Applications:

• Home
• Commercial            

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia Pacific is estimated to increase at the fastest rate and witness significant growth during the forecast period. As a result, the APAC is the second most attractive market for BCG vaccinations; TB incidence is higher in this region due to significant countries like India, Japan, and Malaysia, which account for about 40% of the world's TB population. As a result, the BCG vaccination market in this region. Moreover, the government across the region is initiating awareness programs. 

The China's BCG vaccine market recorded the majority share of the BCG vaccines market, and it is anticipated to register a significant share during the forecast period. The high prevalence of tuberculosis, such as TB eradication programs in emerging nations, is expected to influence market growth positively. In addition, well-established healthcare infrastructure, pharmaceutical research and developments, and supportive government vaccination programs are uplifting the market growth. 

The Indian BCG vaccine market and Japan BCG vaccine market are projected to showcase a considerable share in the market during the forecast period. In addition, a growing emphasis on newborn immunization for protection against severe or deadly infections like TB and rising occurrences of drug-resistant tuberculosis among children and adults are expected to boost the market growth. 

KEY MARKET PLAYERS

The top companies dominating in the APAC BCG Vaccine Market profiled in the report are Merck & Co., Inc., Sanofi Pasteur, China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation), InterVax Ltd, Statens Serum Institute, Japan BCG Laboratory, Serum Institute of India Pvt. Ltd.,